Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)-Reference-Cited by-同舟云学术

Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)

Published:2024-04-10 Issue:7 Volume:65 Page:911-921
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Sancho Juan-Manuel¹^ORCID,Abrisqueta Pau²^ORCID,Kumar Abhijeet³,Cordoba Raul⁴^ORCID,Tani Monica⁵,Langmuir Peter⁶,Rappold Erica⁶,Liu Teng⁶^ORCID,Lopez-Guillermo Armando⁷^ORCID

Affiliation:

1. Clinical Hematology Department, IJC, Hospital Germans Trias i Pujol, Institut Català d‘Oncologia, Barcelona, Spain

2. Department of Hematology, Vall d‘Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d‘Hebron, Barcelona, Spain

3. University of Arizona, Tucson, AZ, USA

4. Lymphoma Unit, Department of Hematology, Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain

5. Haematology Unit Santa Maria delle Croci Hospital, Ravenna, Italy

6. Incyte Corporation, Wilmington, DE, USA

7. Clinic Barcelona, Barcelona, Spain

Funder

Incyte Corporation

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2331626

Reference38 articles.

1. Non-Hodgkin Lymphoma: Diagnosis and Treatment

2. American Cancer Society. Cancer facts & figures. 2022 [cited 2023 Jan 12]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf

3. Non-Hodgkin lymphoma

4. Zelenetz AD Gordon LI Abramson JS et al. NCCN guidelines® B-cell lymphomas version 5.2022. 2022 [cited 2023 Jan 12]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf

5. Genentech, Inc. RITUXAN® (rituximab) injection, for intravenous use [highlights of prescribing information]. South San Francisco (CA): Genentech, Inc.; 2021 [cited 2023 Jan 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf